NCT07206056 2026-04-16
TulmiSTAR-01
Novartis
Phase 1/2 Recruiting
Clinical Trials
13 trialsNCT06855277 2026-02-24
AcTFirst
Novartis
Phase 3 Recruiting
NCT04876651 2026-02-20
The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Terminated
NCT03523338 2025-12-10
An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer
Aragon Pharmaceuticals, Inc.
No longer available
NCT05801965 2025-05-25
A Digital Therapeutic Solution for Cancer Patients
Sidekick Health
Phase NA Completed
NCT06636682 2024-10-21
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
Cellvax Therapeutics Inc
Phase 2 Recruiting
NCT03501173 2023-07-25
GURC
Janssen Inc.
Completed
NCT04446429 2021-12-10
Anti-Androgen Treatment for COVID-19
Applied Biology, Inc.
Phase NA Completed
NCT03323021 2020-11-13
Use of Human Dehydrated Amnion/Chorion (DHACM) Allograft in Partial Nephrectomy
MiMedx Group, Inc.
Phase NA Completed
NCT02187302 2020-05-28
CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
Lumos Pharma
Phase 2 Completed
NCT01310803 2017-10-05
Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder
Endo Pharmaceuticals
Phase 3 Terminated
NCT01353222 2017-05-25
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Dendreon
Phase 2 Terminated
NCT01360840 2015-12-14
PERSEUS
EMD Serono
Phase 2 Completed